Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$17.3B
sum of reported positions
Reported positions
354
Changes vs prior quarter
395
84 new · 85 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 396 measured positions in 8 quarters, the typical new or larger position finished −3.9 pts against the S&P 500 and 42% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 985K | $470M | 2.7% | |
| 6.85M | $322M | 1.9% | |
| 959K | $321M | 1.9% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $13.6B | $17.3B |
| Positions | 355 | 354 |
| Biggest line | — | Taiwan Semiconductor Manufacturing 3% |
| 4.42M |
| $267M |
| 1.5% |
| 786K | $262M | 1.5% |
| 2.8M | $249M | 1.4% |
Crinetics Pharmaceuticals Inc | 6.46M | $242M | 1.4% |
Apogee Therapeutics Inc | 1.74M | $231M | 1.3% |
| 1.53M | $230M | 1.3% |
| 6.72M | $223M | 1.3% |
| 557K | $217M | 1.3% |
| 4.73M | $192M | 1.1% |
| 497K | $189M | 1.1% |
| 1.31M | $187M | 1.1% |
| 229K | $174M | 1.0% |
| 1.77M | $171M | 1.0% |
| 6.16M | $152M | 0.9% |
| 4.43M | $148M | 0.9% |
| 1.21M | $144M | 0.8% |
| 1.56M | $142M | 0.8% |
| 517K | $141M | 0.8% |
| 227K | $140M | 0.8% |
| 4.83M | $140M | 0.8% |
| 1.99M | $138M | 0.8% |
| 355K | $134M | 0.8% |
Transocean (RIG)
7.21M shares in Q1 2026
National Vision Holdings (EYE)
3.47M shares in Q1 2026
Patterson-UTI Energy, Inc. (PTEN)
2.56M shares in Q1 2026
American Resources (AREC)
2.4M shares in Q1 2026
Yum China Holdings (YUMC)
1.83M shares in Q1 2026
Ivanhoe Electric (IE)
1.52M shares in Q1 2026
Ecovyst (ECVT)
1.36M shares in Q1 2026
Oil States International (OIS)
1.33M shares in Q1 2026
Bridgebio Pharma (BBIO)
1.15M shares in Q1 2026
Energy Fuels (UUUU)
1.14M shares in Q1 2026
Perpetua Resources (PPTA)
1.09M shares in Q1 2026
Vistance Networks (VISN)
1.05M shares in Q1 2026
TechnipFMC (FTI)
1.04M shares in Q1 2026
Cg Oncology (CGON)
1000K shares in Q1 2026
Karman Holdings (KRMN)
977K shares in Q1 2026
Methanex (MEOH)
974K shares in Q1 2026
Rocket Companies (RKT)
968K shares in Q1 2026
Xeris Biopharma Holdings (XERS)
903K shares in Q1 2026
Cae (CAE)
900K shares in Q1 2026
Venture Global (VG)
899K shares in Q1 2026
Flowserve (FLS)
803K shares in Q1 2026
Coeur Mining (CDE)
796K shares in Q1 2026
Precigen (PGEN)
794K shares in Q1 2026
Travel + Leisure Co. (TNL)
639K shares in Q1 2026
Jade Biosciences (JBIO)
635K shares in Q1 2026
